Cell engineering

IO360º Summit Honors Women Leaders in Immuno-Oncology R&D

Retrieved on: 
Friday, January 27, 2023
MD, Cell, University, Immunology, Merck, Joint Planning and Development Office, UCSF, Conference, Brooklyn, Cell engineering, Women Leaders in Global Health Conference, Workforce, Publishing, Cancer Research Institute, Massachusetts General Hospital, University of California, San Francisco, Brooklyn Bridge, Woman, Memorial Sloan Kettering Cancer Center, New York Marriott East Side, Organization, Associate professor, Harvard Medical School, Doctor of Philosophy, Science, Nursing, Pharmaceutical industry, Management, Microbiology

NEW YORK, Jan. 27, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced two initiatives to honor women leaders in immuno-oncology including the publishing of the 4th annual "Women Leadership in Immuno-Oncology" and presenting the first-ever Women Leaders in IO Luncheon at the 2023 IO360º meeting on February 8th at the New York Marriott at the Brooklyn Bridge, in Brooklyn, NY.

Key Points: 
  • NEW YORK, Jan. 27, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced two initiatives to honor women leaders in immuno-oncology including the publishing of the 4th annual "Women Leadership in Immuno-Oncology" and presenting the first-ever Women Leaders in IO Luncheon at the 2023 IO360º meeting on February 8th at the New York Marriott at the Brooklyn Bridge, in Brooklyn, NY.
  • "The Women Leadership in Immuno-Oncology series is a sampling of the many incredible women who are working to advance the field of immuno-oncology."
  • The Women Leaders in IO luncheon, February 8, 2023 will include a panel that addresses both the challenges and opportunities for women working in immuno-oncology, such as unconscious bias, negotiation skills and career advice.
  • "We are so pleased to introduce the Women Leaders in IO luncheon to this year's program," said Kate Woda, Senior Director, IO360º, "as a space for women to come together, share key learnings and discuss how to navigate the workforce."

BioCentriq Releases Results of Study Designed to Test Transfection of T-cells Using Kytopen's Flowfect® Technology

Retrieved on: 
Thursday, January 26, 2023
Flow cytometry, Heart, Strategic management, CRISPR, Messenger, DNA, CDMO, GFP, Cell, Partnership, Innovation, Genome-wide CRISPR-Cas9 knockout screens, Transfection, Cell engineering, Gene editing, Growth, Education minister, Vaccine

NEWARK, N.J., Jan. 26, 2023 /PRNewswire/ -- BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they've completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post transfection growth using Kytopen's Flowfect® technology.

Key Points: 
  • NEWARK, N.J., Jan. 26, 2023 /PRNewswire/ -- BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they've completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post transfection growth using Kytopen's Flowfect® technology.
  • The results are published in a white paper titled Efficient, Large-Scale Transfection of T-Cells Using Flowfect® Technology , which was released during last week's Advanced Therapies Week.
  • During the study, which was conducted at BioCentriq by their process development team, cells were transfected with mRNA encoding for GFP, which was analyzed using flow cytometry as a measure of transfection efficiency.
  • Transfection is an invaluable tool used in cell engineering applications to study and modify gene expression by introducing mRNA or DNA into a recipient cell.

Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality

Retrieved on: 
Monday, January 16, 2023
RNP, Data, Cell engineering, Plasmid, RNA transfection, Cas9, Cell membrane, Patient, Ministry of Education (Malaysia), Doctor of Philosophy, Potency (pharmacology), Transfection, GenScript Biotech, GMP, Vaccine, Pharmaceutical industry

Solupore technology works by temporarily permeabilizing the target cell membrane so that molecular cargoes such as mRNA, plasmids, RNP or CRISPR/Cas9 can be delivered while retaining superior cell health and function.

Key Points: 
  • Solupore technology works by temporarily permeabilizing the target cell membrane so that molecular cargoes such as mRNA, plasmids, RNP or CRISPR/Cas9 can be delivered while retaining superior cell health and function.
  • Launching our clinical manufacturing system brings us closer to fulfilling our vision of working with partners to accelerate the future of cell therapies for patients."
  • Caption: Solupore clinical manufacturing system for non-viral delivery to enable next-generation cell therapies.
  • Provides unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery
    Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients

Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review

Retrieved on: 
Wednesday, January 11, 2023
Disclosure, Cell engineering, DNA, Ginkgo, Enzyme, Traction, Total, Growth, Biosafety, NYSE, Safety, Investment, Conference, Fine chemical, Pharmaceutical industry, Seaport District

BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today preliminary performance updates for the year ended December 31, 2022. Among the results, Ginkgo highlighted that it expects to meet its previously disclosed guidance ranges for Total revenue and the commencement of new Cell Programs in 2022 based on its preliminary unaudited estimates. A business review including a discussion of Ginkgo's biopharma capabilities and end-to-end services offerings will be featured in a presentation today at the 41st Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • ET)
    BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today preliminary performance updates for the year ended December 31, 2022.
  • Among the results, Ginkgo highlighted that it expects to meet its previously disclosed guidance ranges for Total revenue and the commencement of new Cell Programs in 2022 based on its preliminary unaudited estimates.
  • A business review including a discussion of Ginkgo's biopharma capabilities and end-to-end services offerings will be featured in a presentation today at the 41st Annual J.P. Morgan Healthcare Conference.
  • Lastly, we ended the year with about $1.3 billion in cash, providing a margin of safety to the business as we continue to scale.

Gameto Expands Executive Team with the Appointment of David McCulloh, Ph.D., H.C.L.D., C.C. as Vice President of Embryology

Retrieved on: 
Tuesday, January 10, 2023
Work, Gynaecology, IVF, Obstetrics, Pain, Egg, Fertility, Medical school, Research, Cell engineering, Sport, Mood Swings, Reproductive medicine, McCulloh, Department of Obstetrics and Gynecology (Massachusetts General Hospital), New York University Grossman School of Medicine, Constipation, ART, Reproduction, University of Miami Division of Surgical Neurooncology, Nausea, Hospital, Oregon Health & Science University, Faculty, Weight gain, Bloating, RMA, University, Therapy, Laboratory, New Jersey Medical School, Lab, Human, School, NYU, Woman, Oocyte, Pharmaceutical industry, Birth control, Embryology

NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Gameto, a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system, today announced the appointment of David McCulloh, Ph.D., H.C.L.D., C.C. as Vice President of Embryology.

Key Points: 
  • NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Gameto, a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system, today announced the appointment of David McCulloh, Ph.D., H.C.L.D., C.C.
  • as Vice President of Embryology.
  • "We are thrilled to have David join our team in New York," said Dina Radenkovic, co-founder and CEO of Gameto.
  • "Gameto's focus on developing a therapeutic that makes IVF and egg freezing shorter, safer, and more effective captivated my attention.

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

Retrieved on: 
Tuesday, January 3, 2023
Cancer, Catamaran, Synthetic biology, Cell engineering, CAR, NK, SPL, LSE, Pharmaceutical industry

Under the terms of the agreement, Catamaran obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Catamaran obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte will receive platform licensing fees and program-related revenue.
  • “The ability to leverage synthetic biology to engineer cell therapies will help drive innovative solutions for solid tumor cancer treatment.
  • MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering.

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Hospitals, Pharmaceutical, Health, PSMA, Eli Lilly and Company, PSCA, Ropes & Gray, Patient, DRS, Social media, Penn, Cooley, Lymphatic system, CAR, University, Invention, Partnership, Cell engineering, EPS, IPR, American Cancer Society, Risk, Centerview Partners, MD, Clinical trial, HIV, ARLA, Non-executive director, Doctor of Philosophy, Gilead Sciences, Hart–Scott–Rodino Antitrust Improvements Act, Research, Cancer, Acquisition, Pharmaceutical industry, Medical imaging, Security (finance), Chewing, Immunotherapy, Medicine, Twitter

Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
  • As part of Kite’s acquisition, the Tmunity founders will become senior scientific advisors for Kite.
  • Kite will acquire all outstanding shares of Tmunity other than those already owned by Kite.
  • As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company.

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Canadian Aviation Regulations, CD137, Cell, NK, CAR, Baylor College of Medicine, SAN, University, Security (finance), Memorial Sloan Kettering Cancer Center, Food, Assistant professor, Safety, Engineering, Cancer, Maintenance, Regulation of tobacco by the U.S. Food and Drug Administration, Multiple myeloma, Toxic shock syndrome, Exposition, ASH, CD38, CD54, Abstract, IPSC, MHC, Destiny, Lymphocyte, CD58, Gene therapy, Immune system, Research, Gene, Society, Ink, Patent, Therapy, Risk, University of Oslo, Lymphatic system, ADR, Daratumumab, BCMA, Cell engineering, Patient, Development, Vaccine

Conditioning chemotherapy, commonly used throughout the field of cell therapy, often results in hematologic toxicities, can limit the potential for administration of multiple doses, and can prohibit adoption as part of early-line treatment.

Key Points: 
  • Conditioning chemotherapy, commonly used throughout the field of cell therapy, often results in hematologic toxicities, can limit the potential for administration of multiple doses, and can prohibit adoption as part of early-line treatment.
  • CD38-targeted monoclonal antibody therapies, such as daratumumab, are approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma.
  • Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

Retrieved on: 
Monday, December 5, 2022
Degenerative disease, LSE, Duchenne muscular dystrophy, Cell, SPL, Glycine, Cell engineering, Therapy, DMD, ALS, Engineering, Biotechnology, Hope, Amyotrophic lateral sclerosis, Expert, Gene, Patient, Pharmaceutical industry, Vaccine, Fine chemical

Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
  • Curamys is a biotechnology company that develops cell & gene therapeutics intended to offer treatment for rare intractable diseases.
  • Currently, Curamys is devoted to develop therapeutics for the treatment of rare diseases, including Duchenne muscular dystrophy, Lou Gehrig’s disease (i.e., amyotrophic lateral sclerosis), and nonketotic hyperglycinemia.

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

Retrieved on: 
Friday, December 2, 2022
Biotechnology, Medicine, Investigational New Drug, COVID-19, Cell engineering, Annual report, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DNA, Gene editing, Patient, Disease, Security (finance), Patent, Food, Pharmaceutical industry, IND, Beam

BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

Key Points: 
  • BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.
  • We believe the future of cell therapy involves high levels of cell engineering, enabled by multiplex base editing technology.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.
  • This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.